Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme

  • Authors:
    • Da Eun Jeong
    • Seon Rang Woo
    • Hyun Nam
    • Do‑Hyun Nam
    • Jae‑Ho Lee
    • Kyeung Min Joo
  • View Affiliations

  • Published online on: October 16, 2017     https://doi.org/10.3892/ol.2017.7196
  • Pages:8213-8219
0

Abstract

The promoter region of the telomerase reverse transcriptase gene (TERT) is mutated in a subpopulation of patients with glioblastoma multiforme (GBM). In the present study, preclinical and clinical implications of the mutation were analyzed in 25 GBMs to evaluate its utility as a therapeutic target. Associations between the TERT promoter mutation and a number of preclinical/clinical characteristics were analyzed. Notably, the TERT promoter mutation was identified in 92.3% of GBMs where dissociated cells revealed in vitro sphere formation capacity; while the TERT promoter mutation was identified in 33.3% of GBMs without in vitro sphere formation capacity (P=0.004). In addition, this significantly increased mutation rate was observed in GBMs with in vivo tumorigenic potential (80% vs. 0%; P=0.004). Furthermore, patients with GBM exhibiting the TERT promoter mutation demonstrated significantly decreased overall survival rate compared with patients lacking this mutation (81.7 vs. 152.6 weeks; P=0.026). The results of the present study indicated that the TERT promoter mutation is associated with the self‑renewal capacity of GBM cells and clinical aggressiveness of GBMs, which may be translated to a targeting therapy against TERT to inhibit the self‑renewal of GBM cells.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jeong, D., Woo, S., Nam, H., Nam, D., Lee, J., & Joo, K. (2017). Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme. Oncology Letters, 14, 8213-8219. https://doi.org/10.3892/ol.2017.7196
MLA
Jeong, D., Woo, S., Nam, H., Nam, D., Lee, J., Joo, K."Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme". Oncology Letters 14.6 (2017): 8213-8219.
Chicago
Jeong, D., Woo, S., Nam, H., Nam, D., Lee, J., Joo, K."Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme". Oncology Letters 14, no. 6 (2017): 8213-8219. https://doi.org/10.3892/ol.2017.7196